Lead clinical

Taken together, these data strongly support the idea that side effects lead clinical-trial patients to realize they have been given the active drug, and that this realization leads them to improve more than patients in the placebo groups. It may not be conclusive proof, but it is strong evidence. 

The early clinical experience, which is described in greater detail in a later section of this chapter, lead clinical investigators to realize that gemcitabine, while able to... 

A series of fluoro-glycosylated fluoroindolocarbazoles was synthesized as selective topoisomerase 1 (topo 1) inhibitors, and the lead clinical candidate from this series, BMS-250749 [28], exhibits broad spectrum antitumor activity superior to Campto-sar against some preclinical xenograft models. BMS-250749 entered into phase 1 clinical trials, but no further developments were reported. 

Klug D, Lacroix D, Savoye C et al (1997) Systemic infection related to endocarditis on pacemaker leads clinical presentation and management. Circulation 95 2098-2107... 

Although most notable in Stein-Leventhal syndrome, which comprises the classical findings of amenorrhea, hirsutism, obesity, and sclerotic ovaries, a wide range of clinical presentations exist. Only one-quarter to one-half of the patients present the classical signs. Usually, infertility is the leading clinical problem of patients with PCOS. Recently, ultrasonographic studies reported a prevalence of polycystic ovaries in young women of at least 20%. However, there seems to be an overlap of polycystic ovaries and normal ovaries [62]. 

Disease Assay Lead Target Lead Clinical FDA... 

No. Disorder Leading clinical symptoms Onset of symptoms (maximum of first manifestation) Frequency... 

Three TLR9 agonists that induce distinct immune response profiles based on their structures have been selected for clinical studies. lMO-2055 is a lead clinical candidate for the treatment of cancers. The safety and pharmacodynamic activity of lMO-2055 have been studied in Phase-1 rising-dose trials in healthy and cancer subjects. A dose-dependent transient migration of lymphocytes from peripheral blood, activation of surface markers on immune cells, and elevation of plasma cytokines has been observed, consistent with immune-stimulatoiy activity of IMO-2055. No significant acute phase or proinflammatory activity, including no effects on cortisol, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), were observed [41, 115-118]. 

Throughout the literature, there are NHC-metal complexes that demonstrate in vitro (and in some cases, in vivo] efficacy greater than that of the leading clinically used drugs. Resistance to current antibiotic and anticancer agents... 

---